India, July 3 -- Alembic Pharmaceuticals announced on Thursday that its US subsidiary, Alembic Pharmaceuticals, Inc., has acquired Utility Therapeutics Ltd in a USD 12 million (over ?100 crore) deal, aimed at strengthening its presence in the American market.
Following the acquisition, Alembic will begin the commercial rollout of Utility's recently FDA-approved drug, Pivya (pivmethecillam), which is used to treat uncomplicated urinary tract infections. The drug received FDA approval in April 2024, the company said in a statement.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....